Khayat D, Bizzari J P, Frenay M, Naman H, Weil M, Goupil A, Namer M, Rouesse J, Banzet P, Jacquillat C
Service d'Oncologie Médicale, Hôpital La Pitié Salpêtrière, Paris, France.
J Natl Cancer Inst. 1988 Nov 2;80(17):1407-8. doi: 10.1093/jnci/80.17.1407.
Thirty-three patients with disseminated malignant melanoma were entered in a phase II study of the new nitrosourea S 10036 using a 100-mg/m2 weekly induction schedule for 3-4 consecutive weeks. Patients who responded to this treatment were followed with a maintenance therapy every 3 weeks. Toxic effects were mainly hematological and consisted of delayed thrombocytopenia and leukopenia. Among 30 patients who could be evaluated, eight partial responses were observed (response rate, 26.67%); among seven patients with cerebral metastasis, two partial responses were observed. This multicentric study is currently being continued to confirm this interim report.
33例播散性恶性黑色素瘤患者进入了一项关于新型亚硝基脲S 10036的II期研究，采用每周100mg/m²的诱导方案，连续3 - 4周。对该治疗有反应的患者每3周接受维持治疗。毒性作用主要为血液学方面，包括延迟性血小板减少和白细胞减少。在30例可评估的患者中，观察到8例部分缓解（缓解率为26.67%）；在7例脑转移患者中，观察到2例部分缓解。这项多中心研究目前仍在继续，以证实这份中期报告。
